Phase II Study of Talazoparib With Androgen Deprivation Therapy and Abiraterone in Castration Sensitive Prostate Cancer
Latest Information Update: 05 Jan 2024
At a glance
- Drugs Abiraterone acetate (Primary) ; Bicalutamide (Primary) ; Degarelix (Primary) ; Goserelin (Primary) ; Leuprorelin (Primary) ; Talazoparib (Primary) ; Prednisone
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- Sponsors Pfizer
- 02 Jan 2024 Planned End Date changed from 15 Dec 2023 to 23 Aug 2027.
- 02 Jan 2024 Planned primary completion date changed from 15 Dec 2023 to 23 Aug 2027.
- 07 Oct 2022 Status changed from active, no longer recruiting to recruiting.